Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
about
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastasesQuantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics.Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease.Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
P2860
Q33683140-88870280-7530-43B4-A77F-30C5956C4126Q34130140-C299CAD9-835E-4FA9-98D3-0235B63E73CEQ35011982-9E5E61B4-B8AB-4B51-A870-A3E5DEB8BFABQ35067584-E05F142E-05D5-461C-8F4B-7D5B0138E2D2Q36107363-E501C89D-26AB-4417-B4B4-DA3044556570Q36593659-4698824D-BB02-4DA1-B3FC-84B2CC90314FQ37020382-6A5C9CE4-0936-47C3-A46F-08F9C1207594Q37576694-F9532F5E-83C7-49DA-8DA5-8DC68650DD80Q38575259-532964B3-C703-46AD-B6E1-2160C4DEA369Q41489396-A340D75D-B6B0-4F35-9363-7934C52BFA04Q41601105-61E94158-24B1-4229-904D-92257E575E7AQ50068024-60D8AD50-9878-4BA7-B582-86B9AAA99508Q55394663-EE84D804-F6BE-443B-B876-82BE552BBCEB
P2860
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Emerging treatment options for ...... itive metastatic breast cancer
@ast
Emerging treatment options for ...... itive metastatic breast cancer
@en
Emerging treatment options for ...... itive metastatic breast cancer
@nl
type
label
Emerging treatment options for ...... itive metastatic breast cancer
@ast
Emerging treatment options for ...... itive metastatic breast cancer
@en
Emerging treatment options for ...... itive metastatic breast cancer
@nl
prefLabel
Emerging treatment options for ...... itive metastatic breast cancer
@ast
Emerging treatment options for ...... itive metastatic breast cancer
@en
Emerging treatment options for ...... itive metastatic breast cancer
@nl
P2860
P921
P1476
Emerging treatment options for ...... itive metastatic breast cancer
@en
P2093
A. Jo Chien
Hope S. Rugo
P2860
P2888
P356
10.1007/S10549-012-2328-6
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1028594863